ExodusPoint Capital Management LP Buys 33,086 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ExodusPoint Capital Management LP raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 22.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 183,395 shares of the medical equipment provider's stock after buying an additional 33,086 shares during the quarter. ExodusPoint Capital Management LP owned 0.09% of Zimmer Biomet worth $19,372,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Roman Butler Fullerton & Co. bought a new stake in Zimmer Biomet during the fourth quarter worth $473,000. Geode Capital Management LLC grew its holdings in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after buying an additional 125,852 shares in the last quarter. M&T Bank Corp grew its stake in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after acquiring an additional 8,709 shares in the last quarter. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet in the fourth quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $654,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZBH. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. JMP Securities reissued a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reaffirmed a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average target price of $124.15.

Remove Ads

Zimmer Biomet Stock Up 0.6 %

ZBH traded up $0.60 during trading on Wednesday, hitting $103.39. 5,689,896 shares of the company's stock traded hands, compared to its average volume of 1,615,393. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $128.55. The company's 50 day simple moving average is $106.54 and its two-hundred day simple moving average is $107.10. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $20.58 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.